肝硬化合并肌少症预测不良预后的研究进展

摘要/Abstract

摘要： 肌少症是肝硬化患者营养不良的常见并发症。肝硬化患者普遍存在肌少症,会降低患者的生活质量、增加住院率并延长住院时间甚至增加死亡率。近年来多项研究显示,肌少症会增加肝硬化相关并发症的发生风险,也是肝移植不良预后的重要影响因素;同时,亦可以作为预测肝硬化相关死亡率的独立危险因素。本文通过对肌少症预测肝硬化相关不良预后的研究进行综述,旨在提高临床工作者对肝硬化肌少症早期的筛查、诊断及干预的重视。

关键词: 肝硬化, 肌少症, 预后, 研究进展

杨蕾, 刘钊瑕, 敬进华, 余虹, 古再努尔·依力亚尔, 李玉玉, 王晓忠, 郭峰. 肝硬化合并肌少症预测不良预后的研究进展[J]. 肝脏, 2025, 30(2): 265-267.

/ 推荐

参考文献

[1] 王俊, 栗凤霞. 肝硬化患者并发肌少症的研究进展[J]. 国际消化病杂志, 2022, 42(5): 283-285+293.
[2] Tantai X, Liu Y, Yeo Y H, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis [J]. J Hepatol, 2022, 76(3): 588-599.
[3] Cruz-Jentoft A J, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 601.
[4] 刘嘉, 黄华. 肝硬化肌肉减少症的发病机制及诊治现状[J]. 临床肝胆病杂志, 2020, 36(4): 895-899.
[5] Asrani S K, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171.
[6] 李侗曾, 孔明, 陈煜. 终末期肝病与肌少症的关系[J]. 临床肝胆病杂志, 2020, 36(3): 693-696.
[7] 张兴会, 郑梦瑶, 杨晋辉. 肝硬化患者肌少症的发生机制及诊疗进展[J]. 临床肝胆病杂志, 2023, 39(9): 2198-2204.
[8] Di Cola S, D'Amico G, Caraceni P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis[J]. J Hepatol, 2024 , 81(4): 641-650.
[9] 李钟浙, 廖晖. 肝硬化患者营养评价及饮食管理研究进展[J]. 实用肝脏病杂志, 2023, 26(4): 601-604.
[10] Zeng X, Shi Z W, Yu J J, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1948-1958.
[11] Topan M M, Sporea I, Dǎnilǎ M, et al. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis[J]. Front Nutr, 2021, 8: 766451.
[12] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
[13] Rodge G A, Goenka U, Jajodia S, et al. Psoas muscle index: a simple and reliable method of sarcopenia assessment on computed tomography scan in chronic liver disease and its impact on mortality[J]. J Clin Exp Hepatol, 2023, 13(2): 196-202.
[14] Dajti E, Renzulli M, Ravaioli F, et al. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis[J]. Dig Liver Dis, 2023, 55(5): 637-643.
[15] Wijarnpreecha K, Werlang M, Panjawatanan P, et al. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2020, 19(3): 245-250.
[16] 敬进华, 孙洁, 余虹, 等. 肝硬化合并肌少症的影响因素分析[J]. 安徽医药, 2024, 28(4): 695-701.
[17] Kikuchi N, Uojima H, Hidaka H, et al. Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology[J]. Hepatol Res, 2021, 51(9): 968-978.
[18] Lee H L, Lee S W. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: advantages and pitfalls[J]. Clin Mol Hepatol, 2022, 28(2): 121-134.
[19] Yin L, Chu S L, Lv W F, et al. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2023, 29(18): 2875-2887.
[20] 杨静仪, 勾熙, 毛小荣, 等. 肌肉减少症对终末期肝病临床结局和预后影响的研究进展[J]. 肝脏, 2022, 27(2): 245-247.
[21] 熊斌, 杨崇图. 肝硬化患者经颈静脉肝内门体分流术与肝硬化肌少症的关系[J]. 临床肝胆病杂志, 2023, 39(7): 1541-1546.
[22] Ganesan P, Kulik L M. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis, 2023, 27(1): 85-102.
[23] Guo Y, Ren Y, Zhu L, et al. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: An updated meta-analysis[J]. Sci Rep, 2023, 13(1): 934.
[24] Perisetti A, Goyal H, Yendala R, et al. Sarcopenia in hepatocellular carcinoma: current knowledge and future directions[J]. World J Gastroenterol, 2022, 28(4): 432-448.
[25] Jiang C, Wang Y, Fu W, et al. Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Front Nutr, 2022, 9: 978110.
[26] 叶晓勇, 周林, 贺强. 2023年中国肝移植基础研究年度盘点[J]. 器官移植, 2024, 15(3): 367-376.
[27] Mendez-Guerrero O, Carranza-Carrasco A, Chi-Cervera L A, et al. Optimizing nutrition in hepatic cirrhosis: a comprehensive assessment and care approach[J]. World J Gastroenterol, 2024, 30(10): 1313-1328.
[28] Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list[J]. Transplantation, 2020, 104(7): e188-e198.
[29] Mauro E, Diaz J M, Garcia-Olveira L, et al. Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list[J]. Hepatol Commun, 2022, 6(7): 1699-1710.
[30] Paternostro R, Bardach C, Hofer B S, et al. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension[J]. Liver Int, 2021, 41(4): 799-809.
[31] Luo J, Yang D, Xu Z, et al. A prospective study on the differential association of sarcopenia and frailty with health outcomes in cirrhotic patients[J]. Dig Liver Dis, 2023, 55(11): 1533-1542.
[32] 周建平, 宋禾. 肌肉减少症对肿瘤病人预后的影响和对策[J]. 中国实用外科杂志, 2024, 44(2): 172-176.
[33] Hui Y, Wang H, Guo G, et al. Association between quality of life defined by EuroQol Group 5 dimension and composite inferior outcome among inpatients with cirrhosis[J]. Clin Interv Aging, 2024, 19: 551-560.
[34] 代梅, 申友书, 赵菲, 等. 肝硬化病人睡眠障碍与肌少症的关联[J]. 护理研究, 2024, 38(5): 892-896.